🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-526995-22-00
Authorised Phase III

Antibiotikapenetration og vævsrespons ved infektion og rekonstruktiv kirurgi i hoved-hals regionen

2026-526995-22-00 · tracked via the Priya Life Science EU tracker
Sponsor
Region Midtjylland
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Bacterial Infections and Mycoses
Decision date
02/09/2026
Enrollment target
16
Sites
Denmark

Condition studied

Treatment and prevention of post operative infections

Investigational medicinal product(s)

CLAVULANIC ACIDAMOXICILLINCLOXACILLINCEFUROXIMEDICLOXACILLIN

Eligibility

Age group
18-64 years
Sex
Female, Male

Primary endpoint

T>MIC for all investigated antibiotics in the measured tissues and in plasma, calculated based on concentration–time profiles obtained from microdialysate samples and serial blood sampling. T>MIC will be calculated using predefined MIC target values for each IMP in the primary analysis: cefuroxime 4 mg/L, cloxacillin 2 mg/L, dicloxacillin 2 mg/L, and amoxicillin/clavulanic acid 2 mg/L, expressed as the amoxicillin component.

Endpoint detail

Pharmacokinetic parameters (Cmax, AUC, Tmax and T½) in tissue and plasma, Concentrations of glucose, lactate, pyruvate and glycerol, as well as inflammatory proteins, in microdialysate samples

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526995-22-00 on CTIS ↗ ← All trials in the EU